FindTrial
Sign In

Pemetrexed 500 mg/m^2

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, CatalYm GmbH

Conditions

Adult Solid TumorCarcinoma, Non-Small-Cell LungMetastatic Non-Squamous Non-Small Cell Lung CancerNeoplasmsNon-small Cell Lung CancerSmall Cell Lung CancerSolid Tumor

Phase 1

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
CompletedNCT01840579
Merck Sharp & Dohme LLCNon-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumor
Start: 2013-04-26End: 2020-02-28Updated: 2021-06-22
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
CompletedNCT02862457
Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung, Neoplasms
Start: 2016-08-23End: 2020-11-20Updated: 2022-08-19

Phase 2

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
CompletedNCT03631784
Merck Sharp & Dohme LLCNon-small Cell Lung Cancer
Start: 2018-10-19End: 2024-03-19Updated: 2025-03-25
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
RecruitingNCT07098988
CatalYm GmbHAdult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer
Start: 2025-08-01End: 2031-03-31Target: 107Updated: 2026-02-27

Related Papers

A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer.
2025-03-03
Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.
Journal of Clinical Oncology2024-06-015 citations
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
2024-03-264 citations
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
2024-02-01
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
Journal of Clinical Oncology2022-06-0127 citations
Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy for Unresectable, Locally Advanced, Stage 3 NSCLC: KEYNOTE-799.
2021-11-01
Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC.
2021-09-153 citations
KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.
Journal of Clinical Oncology2021-05-2016 citations
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
2020-06-209 citations
Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
Journal of Clinical Oncology2020-05-2016 citations
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
Journal of Clinical Oncology2019-05-201 citations
Abstract A204: INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)
Molecular Cancer Therapeutics2018-01-015 citations